Biomm S.A. (BIOMM ON N2) aksje

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina. The company was incorporated in 2001 and is based in Nova Lima, Brazil.